B-CELL MATURATION ANTIGEN (BCMA) TARGETED THERAPIES MARKET ANALYSIS

B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type (CAR-T cell, Bispecific Antibodies, and Antibody Drug Conjugates), by Indication (Acute Lymphoblastic Leukemia, and Multiple Myeloma), and by Geography - Insights, Size, Share, Opportunity Analysis, and Industry Forecast till 2025

Published In : Oct 2017
Code : CMI190
Pages :130
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

However, high cost involved in multiple combinational drug as well as maintenance therapy is expected to hinder growth of the BCMA targeted therapies market.

Increasing number of recurring cases of multiple myeloma is expected to drive growth of the B-cell maturation Antigen (BCMA) targeted therapies market

The patients undergoing chemotherapy and radiation therapy are at high risk of recurrence of cancer as they develop resistance to these therapy. At present there are no treatment options for patients with recurrent cancer and hence the BCMA targeted therapies provide breakthrough therapeutic options for the treatment of relapsed or refractory multiple myeloma, where the existing treatment modalities have proved to be clinically inefficient.